Patents by Inventor Jin-an Jiao

Jin-an Jiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210399290
    Abstract: The present invention provides a silicon-based composite negative electrode material, including an inner core, a first shell layer, and a second shell layer, wherein the first shell layer covers the inner core; the second shell layer covers the first shell cover; the inner core includes a carbon-silicon composite material; the first shell layer includes an amorphous carbon layer; and the second shell layer comprises includes a conductive polymer layer. Meanwhile, further disclosed in the present invention are a preparation method for the silicon-based composite negative electrode material and a lithium ion battery including the silicon-based composite negative electrode material. The silicon-based composite negative electrode material provided in the present invention can effectively restrain the volume expansion of the inner core, construct a stable solid-liquid interface, form a stable SEI film, and improve the cycle stability and multiplier performance of the lithium ion battery.
    Type: Application
    Filed: January 11, 2019
    Publication date: December 23, 2021
    Inventors: Jin Li, Ao Mei, Na He, Qunfeng Wang, Daoping Tang, Yifeng Jiao
  • Publication number: 20210277054
    Abstract: An affinity chromatography resin comprising an anti-tissue factor antibody or antigen-binding fragment thereof attached to a base resin, and methods of using the same.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 9, 2021
    Inventors: Hing C. Wong, Jin-an Jiao, Caitlin Prendes
  • Publication number: 20150010558
    Abstract: Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF) to form a complex in which factor X or factor IX binding to the complex is inhibited and the administration is sufficient to prevent or treat the sepsis in the mammal. The invention has a wide spectrum of useful applications including treating sepsis, disorders related to sepsis, and inflammatory diseases such as arthritis.
    Type: Application
    Filed: February 11, 2014
    Publication date: January 8, 2015
    Applicant: GENENTECH, INC.
    Inventors: Jin-An JIAO, Hing C. WONG, Jack O. EGAN
  • Publication number: 20130011389
    Abstract: Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF) to form a complex in which factor X or factor IX binding to the complex is inhibited and the administration is sufficient to prevent or treat the sepsis in the mammal. The invention has a wide spectrum of useful applications including treating sepsis, disorders related to sepsis, and inflammatory diseases such as arthritis.
    Type: Application
    Filed: December 15, 2011
    Publication date: January 10, 2013
    Inventors: Jin-An JIAO, Hing C. Wong, Jack O. Egan
  • Patent number: 8007795
    Abstract: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor X or FIX binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site. Also provided are humanized antibodies and fragments thereof that bind to the TF.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: August 30, 2011
    Assignee: Genentech, Inc.
    Inventors: Jin-an Jiao, Hing C. Wong, Esperanza Liliana Nieves, Luis A. Mosquera
  • Publication number: 20110182900
    Abstract: Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF) to form a complex in which factor X or factor IX binding to the complex is inhibited and the administration is sufficient to prevent or treat the sepsis in the mammal. The invention has a wide spectrum of useful applications including treating sepsis, disorders related to sepsis, and inflammatory diseases such as arthritis.
    Type: Application
    Filed: January 25, 2011
    Publication date: July 28, 2011
    Inventors: Jin-An JIAO, Hing C. Wong, Jack O. Egan
  • Patent number: 7968094
    Abstract: Disclosed is a method for preventing or treating thrombosis in a mammal such as a primate and particularly a human patient. A preferred method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to human tissue factor (TF). Additional methods and kits are provided.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: June 28, 2011
    Assignee: Genentech, Inc.
    Inventors: Jin-An Jiao, Hing C. Wong, Esperanza Liliana Nieves, Luis A. Mosquera
  • Publication number: 20110138677
    Abstract: A mouse catcher includes a container for accommodating two or more mice therewithin, a one directional tunnel, and a one directional mechanism. The tunnel is communicatively connected to the container for guiding the mouse passing from the tunnel into the container through a door entrance. The one directional mechanism is provided for allowing the mouse entering only from the one directional tunnel into the container, wherein the one directional mechanism includes a one way gate movably coupling at the door entrance for communicatively guiding the mouse entering only from the tunnel to the container through the one way gate in the one way manner. A bait vessel is further provided within the container for luring the mouse entering the one way gate into the container for being caught, so that the mouse is caught alive, so as to lure another mouse entering container.
    Type: Application
    Filed: December 16, 2009
    Publication date: June 16, 2011
    Inventors: Heng Jin Jiao, Tsung Yen Wu
  • Publication number: 20110104184
    Abstract: Disclosed are antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Also disclosed are methods of using such antibodies to reduce cancer cell tissue factor activity and to detect cancer cells that express TF.
    Type: Application
    Filed: December 23, 2009
    Publication date: May 5, 2011
    Applicant: GENENTECH, INC.
    Inventors: JIN-AN JIAO, HING C. WONG, JINGHAI WEN
  • Patent number: 7824677
    Abstract: The invention includes methods of inhibiting blood coagulation using antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Methods of the invention can effectively inhibit blood coagulation in vivo. Antibodies used in the methods of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies used in the methods of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.
    Type: Grant
    Filed: June 10, 2008
    Date of Patent: November 2, 2010
    Assignee: Genentech, Inc.
    Inventors: Hing C. Wong, Jin-An Jiao, Esperanza Liliana Nieves, Lawrence Luepschen
  • Patent number: 7749498
    Abstract: Disclosed are antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Also disclosed are methods of using such antibodies to reduce cancer cell tissue factor activity and to detect cancer cells that express TF.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: July 6, 2010
    Assignee: Genentech, Inc.
    Inventors: Jin-an Jiao, Hing C. Wong, Jinghai Wen
  • Publication number: 20090252726
    Abstract: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor X or FIX binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site. Also provided are humanized antibodies and fragments thereof that bind to the TF.
    Type: Application
    Filed: March 13, 2009
    Publication date: October 8, 2009
    Inventors: Jin-an JIAO, Hing C. Wong, Esperanza Liliana Nieves, Luis A. Mosquera
  • Publication number: 20090136501
    Abstract: Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF) to form a complex in which factor X or factor IX binding to the complex is inhibited and the administration is sufficient to prevent or treat the sepsis in the mammal. The invention has a wide spectrum of useful applications including treating sepsis, disorders related to sepsis, and inflammatory diseases such as arthritis.
    Type: Application
    Filed: February 22, 2008
    Publication date: May 28, 2009
    Inventors: Jin-An JIAO, Hing C. Wong, Jack O. Egan
  • Publication number: 20090092602
    Abstract: Disclosed is a method for preventing or treating thrombosis in a mammal such as a primate and particularly a human patient. A preferred method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to human tissue factor (TF). Additional methods and kits are provided.
    Type: Application
    Filed: July 31, 2008
    Publication date: April 9, 2009
    Inventors: Jin-an JIAO, Hing C. WONG, Esperanza Liliana NIEVES, Luis A. MOSQUERA
  • Publication number: 20090041766
    Abstract: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.
    Type: Application
    Filed: June 10, 2008
    Publication date: February 12, 2009
    Inventors: Hing C. Wong, Jin-An Jiao, Esperanza Liliana Nieves, Lawrence Luepschen
  • Publication number: 20070155703
    Abstract: The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treatment or prophylaxis of undesired thrombosis.
    Type: Application
    Filed: February 15, 2007
    Publication date: July 5, 2007
    Applicant: Tanox, Inc.
    Inventors: Jin-An Jiao, Lawrence Luepschen, Esperanza Nieves, Hing Wong, Dean Taylor
  • Patent number: 7199113
    Abstract: The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treatment or prophylaxis of undesired thrombosis.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: April 3, 2007
    Inventors: Jin-An Jiao, Lawrence K. Luepschen, Esperanza Nieves, Hing C. Wong, Dean P. Taylor
  • Patent number: 7141656
    Abstract: The present invention relates to novel complexes of major histocompability complex (MHC) molecules and uses of such complexes. In one aspect, the invention relates to loaded MHC complexes that include at least one MHC molecule with a peptide-binding groove and a presenting peptide non-covalently linked to the MHC protein. In another aspect, the invention features single chain MHC class II peptide fusion complexes with a presenting peptide covalently linked to the peptide binding grove of the complex. MHC complexes of the invention are useful for a variety of applications including: 1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and 2) methods for suppressing or inducing an immune response in a mammal.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: November 28, 2006
    Assignee: Altor Bioscience Corporation
    Inventors: Peter R. Rhode, Jin-An Jiao, Martin Burkhardt, Hing C. Wong
  • Publication number: 20060235209
    Abstract: Disclosed is a method for preventing or treating thrombosis in a mammal such as a primate and particularly a human patient. A preferred method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to human tissue factor (TF). Additional methods and kits are provided.
    Type: Application
    Filed: December 4, 2002
    Publication date: October 19, 2006
    Inventors: Jin-An Jiao, Hing Wong, Esperanza Nieves, Luis Mosquera
  • Publication number: 20060159675
    Abstract: Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF) to form a complex in which factor X or factor IX binding to the complex is inhibited and the administration is sufficient to prevent or treat the sepsis in the mammal. The invention has a wide spectrum of useful applications including treating sepsis, disorders related to sepsis, and inflammatory diseases such as arthritis.
    Type: Application
    Filed: December 19, 2005
    Publication date: July 20, 2006
    Inventors: Jin-An Jiao, Hing Wong, Jack Egan